Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities
Net loss for basic and diluted loss per share available to common stockholders	$ (24,377)	$ (30,753)
Adjustments to reconcile net loss to net cash proceeds from (used for) operating activities:
Depreciation and amortization	1,031	1,037
Amortization of debt issuance costs and debt discount	31	0
Non-cash operating lease cost	180	144
Stock-based compensation	3,558	3,720
Loss on derivative liability	457	5,253
Allocated expenses for warrant issuance cost	1,375	0
Change in fair value of debt and liability instruments	3,905	0
Other	26	0
Changes in operating assets and liabilities:
Accounts receivables, net	4,881	1,992
Inventory	726	(897)
Prepaid expenses and other	(39)	294
Other long-term assets	(30)	997
Accounts payable	1,265	2,001
Accrued Payroll	1,046	359
Accrued expenses	1,120	3,543
Accrued rebates and fees	14,430	4,736
Other liabilities	(197)	(175)
Other long-term liabilities	3	5
Net cash proceeds from (used for) operating activities	9,391	(7,744)
Investing activities
Acquisition consideration paid in cash for Romeg intangible asset acquisition	(150)	0
Net cash used for investing activities	(150)	0
Financing activities
Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement	156	1,663
Proceeds from issuance of Convertible Debentures	0	9,600
Proceeds from issuance of Revolving Facility	32,567	0
Repayment of Revolving Facility	(33,313)	0
Repayment of Oramed Note	(15,000)	0
Transaction costs paid related to the Business Combination	0	(634)
Repayment of Convertible Debentures	(4,375)	0
Proceeds from issuance of shares under Bought Deal Offering	10,000
Payments of Bought Deal Offering issuance costs	(1,277)	0
Proceeds from stock options exercised	46	0
Net cash (used for) proceeds from financing activities	(11,196)	10,629
Net change in cash, cash equivalents and restricted cash	(1,955)	2,885
Cash and cash equivalents at beginning of period	4,729	2,184
Cash and cash equivalents at end of period	2,774	5,069
Supplemental disclosure of non-cash financing activity
Issuance of shares to B.Riley pursuant to B. Riley Purchase Agreement	0	1,869
Issuance costs related to Bought Deal Offering included in accrued expenses	$ 1,501	$ 0